About Organigram Global Inc. - Common Shares (OGI)
Organigram Holdings Inc. is a Canadian licensed producer of cannabis, focused on the development and cultivation of high-quality marijuana products for both medical and recreational markets. The company operates state-of-the-art facilities that utilize advanced technology and sustainable practices to grow and produce a variety of cannabis strains, including dried flower and cannabis oils. Organigram is committed to innovation in product development, creating a wide range of cannabis-infused products such as edibles, beverages, and vape oils. With a strong emphasis on compliance, quality control, and consumer education, Organigram aims to be a leading player in the evolving cannabis industry while promoting responsible use and supporting community initiatives. Read More
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram Global”), the cannabis leader in Canada by market share, is pleased to announce its inaugural virtual investor event, the OG Investor Session, taking place on April 10, 2025, at 4pm EST. This online event offers investors a front-row seat to Organigram Global’s next chapter. Attendees will gain valuable insights into the Company’s growth trajectory, engage directly with leadership on key industry trends, and get a behind-the-scenes look at the innovation and strategy driving Organigram Global forward.
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), Canada’s #1 cannabis company by market share, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Collective Project Limited (“CPL”) for upfront consideration of approximately C$6.2 million, potential milestone payments and potential earnout payments totaling in the aggregate up to C$24M for the twelve-month periods ending September 30, 2025 and September 30, 2026.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, is proud to announce its official rebrand to Organigram Global Inc. (“Organigram Global”), a move that demonstrates the Company’s evolution from an East Coast medical cannabis company into a burgeoning global cannabis leader.
Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI) (NASDAQ: OGI) announced today the results of voting at its annual general and special meeting of shareholders (the “Shareholders”) held virtually on March 24, 2025 (the “Meeting”).
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that on February 28, 2025, the Company closed the third and last of three tranches (the “Third Tranche”) of the previously announced C$124,559,674 follow-on strategic equity investment (the “Investment”) by BT DE Investments Inc. (the “Investor”), a wholly owned subsidiary of British American Tobacco plc (“BAT”). Pursuant to the Third Tranche closing, the Investor acquired 7,562,447 common shares (the “Common Shares”) and 5,330,728 Class A preferred shares (the “Preferred Shares” and together with the Common Shares, the “Shares”) of the Company at a price of C$3.2203 per Share (the “Per Share Price”) for gross proceeds of USD$28,955,918.44 (equal to C$41,519,891)1.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended December 31, 2024 (“Q1 Fiscal 2025”). The Q1 Fiscal 2025 results include the financial results of Motif Labs Ltd. ("Motif") from December 6, 2024 to December 31, 2024, following the Company's acquisition of Motif.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2025 ended December 31, 2024, on Tuesday, February 11, 2025, prior to market open.
DEA judge orders agency to respond to allegations of opposing marijuana rescheduling and improper communication with opponents. Cannabis stocks declined in 2024 due to concerns about DEA review.
This earnings release replaces the previously filed earnings release on December 18, 2024 to correct errors in the outstanding share data tables under the heading “CAPITAL STRUCTURE.” No other changes are being made. The Company is also refiling its Management’s Discussion and Analysis for the twelve months ended September 30, 2024 to correct corresponding errors in the outstanding share data table, which corrections will also apply to the MD&A included in the Company’s Annual Report filed on December 18, 2024.
Organigram's Q4 sales hit $31.22 million, boosted by recreational and international growth, with adjusted gross margin improving to 37% of net revenue.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open.
